Jun Liang
Peking University
10 Papers
Jun Liang is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Feng Wang,Xiao‐Tian Zhang,Lei Tang,Qi Wu,Mu-Yan Cai,Yuan-Fang Li,Xiu‐Juan Qu,Hongyong Qiu,Yu-Jing Zhang,Jieer Ying,Jun Zhang,Ling-yu Sun,Rong-Bo Lin,Chang Wang,Hao Liu,Miao Zhen Qiu,Wen-Long Guan,Sheng-Xiang Rao,Jiafu Ji,Yan Xin,Wei‐Qi Sheng,Hui-Mian Xu,Zhi-Wei Zhou,Ai‐Ping Zhou,Jing Jin,Xianglin Yuan,Feng Bi,Tian-Shu Liu,Han Liang,Yan-Qiao Zhang,Guo-Xin Li,Jun Liang,Baorui Liu,L. Shen,Jin Li,Rui-Hua Xu +35 more
TL;DR: The 2023 CSCO Clinical Guidelines for Gastric Cancer provide comprehensive and updated recommendations for diagnosis and treatment, incorporating the latest advancements in evidence-based medicine and precision medicine.
119
Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer
TL;DR: IAPs were strong prognostic factors for patient survival and tumor stage in several tumor types including brain, liver, kidney, breast and lung cancer and were found to be predictive of sensitivity to BCL-2 inhibitors.
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.
Zhenggang Ren,Yabing Guo,Y. Bai,Jieer Ying,Zhiqiang Meng,Zhendong Chen,Shanzhi Gu,Jingdong Zhang,Jun Liang,Xin Hou,Wei Liu,Aibing Xu,Chunyi Hao,Jian Zhang,Ruijun Xing,Xinyu Zhang,Danlu Zhang,Stephen Chan +17 more
TL;DR: In this paper , a single-arm, phase 1/2 dose escalation and expansion study was conducted to assess the safety and efficacy of tebotelimab in patients with advanced hepatocellular carcinoma.
10
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).
Jun Guo,Shukui Qin,Jun Liang,Tong Yu Lin,Lu Si,Xiaohong Chen,Zhihong Chi,Chuanliang Cui,Nan Du,Yun Fan,Kangsheng Gu,Fang Li,Junling Li,Yongheng Li,Houjie Liang,Jiwei Liu,Man Lu,A. Lu,Kejun Nan,Xiaohui Liu,Hongming Pan,Guoxin Ren,Xiubao Ren,Yongqian Shu,Xing Song,Min Tao,Baocheng Wang,Wenbin Wei,Di Wu,Lingying Wu,Aiwen Wu,Xiaolin Xu,Junyi Zhang,Xiaoshi Zhang,Yiping Zhang,Huiyan Zhu +35 more
TL;DR: The 2015 edition of the Chinese Guidelines on the Diagnosis and Treatment of Melanoma was finalized after repeated and wide consultations with multidisciplinary experts and updated and added with much new information, with an attempt to provide the up-todated and reliable instructions on clinical practices based recent scientific evidences.
8
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
Shun Lu,Ying Cheng,Jianying Zhou,Mengzhao Wang,Jun Zhao,Baocheng Wang,Gongyan Chen,Jifeng Feng,Zhiyong Ma,Lin Wu,Changli Wang,Kewei Ma,Shucai Zhang,Jun Liang,Yong Song,Jie Wang,Yi-Long Wu,Ang Li,YiZhi Huang,Jianhua Chang +19 more
TL;DR: Wang et al. as mentioned in this paper investigated the safety and efficacy of flat-dose nivolumab in patients with advanced NSCLC, including those with hepatitis B virus (HBV) and epidermal growth factor receptor (EGFR) mutation/ALK receptor tyrosine kinase (ALK) translocation.
5